Review
Oncology
Alejandro Garcia-Alvarez, Andri Papakonstantinou, Mafalda Oliveira
Summary: Development of brain metastases is a significant event for patients with breast cancer, particularly those with HER2-positive tumors. Advances in targeted therapy against the HER2 receptor have improved management of HER2-positive breast cancer. Despite these improvements, brain metastases continue to be a challenge, highlighting the need for further research and innovative treatment strategies.
Review
Oncology
Natalia Krawczyk, Tanja Fehm, Eugen Ruckhaeberle, Laura Brus, Valeria Kopperschmidt, Achim Rody, Lars Hanker, Maggie Banys-Paluchowski
Summary: The response to neoadjuvant treatment is crucial for the clinical outcome of breast cancer patients, especially in the HER2-positive subtype. Selecting postoperative therapies based on tumor response significantly impacts patient prognosis.
Review
Oncology
Daniele Galanti, Alessandro Inno, Maria La Vecchia, Nicolo Borsellino, Lorena Incorvaia, Antonio Russo, Stefania Gori
Summary: Brain metastases are often associated with HER2+ breast cancer, and systemic therapy with trastuzumab has been the mainstay. Other HER2-targeted agents have been introduced in clinical practice, with newer agents such as neratinib, tucatinib, and trastuzumab deruxtecan showing interesting activity against brain metastases. Further research is needed to elucidate the optimal sequence of these agents and their combination with local treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Oncology
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Summary: Triple-positive breast tumors overexpress HER2 and are positive for HR expression. ER expression affects the response to anti-HER2 and associated systemic therapies. Optimizing dual anti-HER2 blockade is important for disease control in triple-positive tumors.
CANCER TREATMENT REVIEWS
(2023)
Review
Pharmacology & Pharmacy
Xiaofan Wu, Hongjian Yang, Xingfei Yu, Jiang-Jiang Qin
Summary: Breast cancer is a common malignancy in women, and HER2 overexpression is associated with poor prognosis. Pertuzumab and trastuzumab are the primary treatment options for early-stage HER2-positive breast cancer, and antibody-drug conjugates and tyrosine kinase inhibitors improve prognosis for metastatic breast cancer patients. However, resistance to targeted therapy is an issue that needs to be addressed.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, Jacques Raphael, Phillip Blanchette, Abdullah Al-Humiqani, Monali Ray
Summary: HER2-positive breast cancer is aggressive and has a poor prognosis. Standard chemotherapy with HER2 blockers can improve outcomes and increase the suitability for breast-conserving surgery. It is crucial to identify patients who should receive systemic cancer treatment and decide the most appropriate option for each case.
Review
Biochemistry & Molecular Biology
Ivanna Hrynchak, Liliana Santos, Amilcar Falcao, Celia M. Gomes, Antero J. Abrunhosa
Summary: This review highlights the unique characteristics and advantages of Nb-based radiotracers in breast cancer imaging and therapy, while also discussing radiolabeling methods for Nb and their promising prospects as theranostic agents.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Ismail Essadi, Zineb Benbrahim, Mohamed Kaakoua, Thibaut Reverdy, Pauline Corbaux, Gilles Freyer
Summary: Since the advent of trastuzumab, the natural history of HER2-positive metastatic breast cancer has improved. Various therapies targeting HER2 have been developed, including anti-HER2 double blockade and trastuzumab-deruxtecan, which have improved overall survival. However, the benefit of these therapies in patients with brain metastases is still unclear. The introduction of tucatinib, a new tyrosine kinase inhibitor, has shown promise for the treatment of these patients. This article reviews established drugs and novel agents for HER2-positive MBC and discusses their incorporation into different treatment settings.
Article
Oncology
Johanna E. Poterala, Thomas Havighurst, Kari Braun Wisinski
Summary: This retrospective study reviewed the pathologic complete response (pCR) in patients with weak hormone receptor-positive and HER2-negative breast cancer following neoadjuvant chemotherapy. The pCR in this population resembled rates seen in triple negative breast cancer more so than strong hormone receptor-positive disease. Increased pCR in this population may provide important prognostic information, highlighting the need for clinical trials focusing on this unique patient cohort.
CLINICAL BREAST CANCER
(2022)
Article
Oncology
Nadia Harbeck, Harold J. Burstein, Sara A. Hurvitz, Stephen Johnston, Gregory A. Vidal
Summary: The heterogeneity of hormone receptor (HR)-positive, HER2-negative early breast cancers highlights the importance of personalized treatment approaches. Patients with high-risk features have an elevated risk for recurrence despite standard care. Adding cyclin-dependent kinase 4 and 6 inhibitors to endocrine therapy shows promise in improving outcomes for this difficult to treat patient population.
Review
Oncology
Sonia Pernas, Sara M. Tolaney
Summary: An understanding of tumor biology and HER2 signaling has led to the development of effective anti-HER2 drugs, improving the prognosis of patients with HER2-positive breast cancer. The immune microenvironment and host immune system also play important roles in prognosis and treatment response. This review presents the latest evidence and emerging strategies of immunotherapy in HER2-positive breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Joohyun Hong, Yeon Hee Park
Summary: Significant progress has been made in the treatment of HER2-positive breast cancer, especially with the development of targeted therapies. Different treatment approaches are applied based on the risk level and presence of residual disease, including adjuvant trastuzumab, pertuzumab, paclitaxel, and other drugs. Ongoing trials are exploring the combination of novel agents and de-escalation of treatment in the neoadjuvant setting, aiming to achieve better outcomes.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sandeep Pallerla, Ata ur Rahman Mohammed Abdul, Jill Comeau, Seetharama Jois
Summary: Breast cancer is a major cause of death in women, with improvements in targeted therapies but still facing issues of resistance and limitations. Vaccine therapy introduces antigens to activate the immune system, providing longer-term immune memory to prevent cancer relapse.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Maria Gaibar, Apolonia Novillo, Alicia Romero-Lorca, Diego Malon, Beatriz Anton, Amalia Moreno, Ana Fernandez-Santander
Summary: This study aimed to investigate the correlation between copy number variations (CNVs) in several genes related to the PI3K/AKT pathway and the efficacy of anti-HER2 neoadjuvant treatment in early HER2-positive breast cancer patients. The findings suggest that patients with FGFR1 amplification might benefit less from anti-HER2 antibody therapy.
Review
Oncology
Kreina Sharela Vega Cano, David Humberto Marmolejo Castaneda, Santiago Escriva-de-Romani, Cristina Saura
Summary: Therapeutic advances have significantly improved the natural history of HER2-positive metastatic breast cancer. Double anti-HER2 blockade with a taxane is currently the best option in first-line, but T-DXd has emerged as the new standard in second-line. New treatments and combinations are being developed to address resistance and progress in these patients.